|Bid||1.2500 x 1000|
|Ask||1.3800 x 1100|
|Day's Range||1.2500 - 1.3000|
|52 Week Range||0.7500 - 6.0400|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||9.35|
|Earnings Date||Jun 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CHINA NATURAL RESOURCES, INC. (NASDAQ: CHNR) (the "Company") today announced its results of operations for the year ended December 31, 2020. For the convenience of the reader, amounts in Chinese Yuan ("CNY") have been translated into United States dollars ("US$") at the rate of US$1.00 = CNY6.5306 as quoted by www.ofx.com on December 31, 2020.
China Natural Resources, Inc. (NASDAQ: CHNR) (the "Company") announced today the appointment of pharmaceutical industry executive Peng Wenlie as Vice President, effective March 22, 2021. Dr. Peng, who brings more than 20 years of experience working in the industry, will report directly to the Company's Chairman, Mr. Wong Wah On Edward. He will be responsible for evaluating the Company's investment opportunities in the healthcare, biomedicine, and related markets.
CHINA NATURAL RESOURCES, INC. (NASDAQ: CHNR) (the "Company") today announced that it closed the registered direct offering of approximately $7.3 million of common shares at a price of $1.85 per share on January 22, 2021, as previously announced on January 20, 2021. The Company issued a total of 3,960,000 common shares to the institutional investors participating in the offering. In a concurrent private placement, the Company also issued warrants ("Warrants") to the investors, initially exercisable for the purchase of up to 1,584,000 common shares at an exercise price of $2.35 per share, which Warrants have a term of 36 months from the date of issuance. The net proceeds from this offering will be used for general corporate purposes.